Madrigal Pharmaceuticals Inc
MDGL
ISIN US5588681057 / Valor 33395434
Madrigal Pharmaceuticals Inc
UMushroom community rating:
About company
Madrigal Pharmaceuticals Inc. is a biopharmaceutical entity focused on the development of innovative treatments for nonalcoholic steatohepatitis (NASH), a condition also referred to as metabolic dysfunction associated steatohepatitis (MASH). The company has made significant strides in this therapeutic area, with its first therapy receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults exhibiting moderate to advanced liver fibrosis, which corresponds to stages F2 to F3 fibrosis, a critical subset of the NASH patient population. Furthermore, Madrigal is advancing its research and development efforts by conducting a Phase 3 trial aimed at evaluating the efficacy of its therapy in treating NASH with compensated cirrhosis, demonstrating its commitment to addressing the unmet medical needs within this patient community.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
6916 M
Market cap (USD)
94,097
Daily traded volume (Shares)
322.8 / 312.62
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
